Quantifying CDK inhibitor selectivity in live cells
暂无分享,去创建一个
T. Willson | D. Drewry | C. Wells | C. Zimprich | K. Huber | B. Hwang | Marie K Schwinn | M. Robers | J. Pickett | J. Vasta | H. Zegzouti | P. Meisenheimer | Cesear R. Corona | J. Wilkinson | M. Cong | Morgan R. Ingold | Kathryn M Pugh | Chad A. Zimprich
[1] M B Robers,et al. Quantifying Target Occupancy of Small Molecules Within Living Cells. , 2020, Annual review of biochemistry.
[2] S. Goueli,et al. A homogeneous bioluminescent immunoassay to probe cellular signaling pathway regulation , 2020, Communications Biology.
[3] David J. Fallon,et al. A Photoaffinity Displacement Assay and Probes to Study the Cyclin-Dependent Kinase Family. , 2019, Angewandte Chemie.
[4] Concha Sánchez-Martínez,et al. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019). , 2019, Bioorganic & medicinal chemistry letters.
[5] A. Lin,et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials , 2019, Science Translational Medicine.
[6] Sarah A. Boswell,et al. Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. , 2019, Cell chemical biology.
[7] David A. Orlando,et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. , 2019, Cancer research.
[8] Jared L. Johnson,et al. Discovery of Covalent CDK14 Inhibitors with Pan-TAIRE Family Specificity. , 2019, Cell chemical biology.
[9] Haopeng Sun,et al. CDK8 as a therapeutic target for cancers and recent developments in discovery of CDK8 inhibitors. , 2019, European journal of medicinal chemistry.
[10] W. Tilley,et al. Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update. , 2018, Journal of medicinal chemistry.
[11] K. Comess,et al. Quantitative, Real-Time Measurements of Intracellular Target Engagement Using Energy Transfer. , 2018, Methods in molecular biology.
[12] S. Knapp,et al. Binding Kinetics Survey of the Drugged Kinome. , 2018, Journal of the American Chemical Society.
[13] V. Kryštof,et al. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? , 2018, Journal of medicinal chemistry.
[14] M. Mcdougall,et al. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action. , 2018, ACS chemical biology.
[15] J. Fins. Family Portrait , 2018, Narrative inquiry in bioethics.
[16] N. Gray,et al. Kinase inhibitors: the road ahead , 2018, Nature Reviews Drug Discovery.
[17] Simak Ali,et al. ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment , 2018, Molecular Cancer Therapeutics.
[18] Robert A Copeland,et al. The Elements of Translational Chemical Biology. , 2017, Cell chemical biology.
[19] T. Willson,et al. Quantitative, Wide-Spectrum Kinase Profiling in Live Cells for Assessing the Effect of Cellular ATP on Target Engagement , 2017, Cell chemical biology.
[20] Kris Zimmerman,et al. CRISPR-Mediated Tagging of Endogenous Proteins with a Luminescent Peptide. , 2017, ACS chemical biology.
[21] Heiner Koch,et al. The target landscape of clinical kinase drugs , 2017, Science.
[22] Jian Du,et al. Preclinical characterization of abemaciclib in hormone receptor positive breast cancer , 2017, Oncotarget.
[23] P. Workman,et al. Inhibitors of cyclin‐dependent kinases as cancer therapeutics , 2017, Pharmacology & therapeutics.
[24] Stephen J. Capuzzi,et al. Progress towards a public chemogenomic set for protein kinases and a call for contributions , 2017, bioRxiv.
[25] N. Gray,et al. THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors , 2017, Nature Communications.
[26] A. Burlingame,et al. Broad-Spectrum Kinase Profiling in Live Cells with Lysine-Targeted Sulfonyl Fluoride Probes. , 2017, Journal of the American Chemical Society.
[27] S. Chandarlapaty,et al. Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence , 2016, Oncogene.
[28] G. Vauquelin. Effects of target binding kinetics on in vivo drug efficacy: koff, kon and rebinding , 2016, British journal of pharmacology.
[29] R. Finn,et al. Treating cancer with selective CDK4/6 inhibitors , 2016, Nature Reviews Clinical Oncology.
[30] P. Lienau,et al. Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9. , 2016, ACS chemical biology.
[31] K. Bowman,et al. Design and Development of a Series of Potent and Selective Type II Inhibitors of CDK8. , 2016, ACS medicinal chemistry letters.
[32] Brock F. Binkowski,et al. NanoLuc Complementation Reporter Optimized for Accurate Measurement of Protein Interactions in Cells. , 2016, ACS chemical biology.
[33] M. Kinch,et al. An analysis of FDA-approved drugs: natural products and their derivatives. , 2016, Drug discovery today.
[34] Julian Blagg,et al. Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19 , 2016, Journal of medicinal chemistry.
[35] M. Clausen,et al. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. , 2016, Drug discovery today.
[36] K. Wood,et al. Target engagement and drug residence time can be observed in living cells with BRET , 2015, Nature Communications.
[37] Gary Box,et al. A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease , 2015, Nature chemical biology.
[38] Rosanne Raso,et al. Changing a paradigm. , 2015, Nursing management.
[39] L. Gelbert,et al. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs. , 2015, Bioorganic & medicinal chemistry letters.
[40] C. Deane,et al. Type II Inhibitors Targeting CDK2. , 2015, ACS chemical biology.
[41] Peter J Tonge,et al. Translating slow-binding inhibition kinetics into cellular and in vivo effects. , 2015, Nature chemical biology.
[42] Leigh A. Stoddart,et al. Application of BRET to monitor ligand binding to GPCRs , 2015, Nature Methods.
[43] Agnieszka K. Witkiewicz,et al. The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.
[44] K. Korn,et al. A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations , 2015, Antimicrobial Agents and Chemotherapy.
[45] M. Drysdale,et al. A novel small-molecule MRCK inhibitor blocks cancer cell invasion , 2014, Cell Communication and Signaling.
[46] M. Malumbres,et al. Cyclin-dependent kinases , 2014, Genome Biology.
[47] Sridhar Ramaswamy,et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor , 2014, Nature.
[48] Alastair J. King,et al. Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. , 2013, ACS medicinal chemistry letters.
[49] S. Baumli,et al. Perspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target , 2012, Current pharmaceutical design.
[50] A. Futatsugi,et al. Cyclin-dependent kinase 5 regulates E2F transcription factor through phosphorylation of Rb protein in neurons , 2012, Cell cycle.
[51] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[52] G. Vauquelin. Rebinding: or why drugs may act longer in vivo than expected from their in vitro target residence time , 2010, Expert opinion on drug discovery.
[53] Li-Huei Tsai,et al. Cyclin-dependent kinases: a family portrait , 2009, Nature Cell Biology.
[54] J. Snyder,et al. The development of a selective cyclin-dependent kinase inhibitor that shows antitumor activity. , 2009, Cancer research.
[55] A. Tefferi,et al. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients , 2009, Leukemia.
[56] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[57] J. Lyons,et al. Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines , 2009, Molecular Cancer Therapeutics.
[58] Pablo Tamayo,et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity , 2008, Nature.
[59] Dwight M. Morrow,et al. Discovery of novel and long acting muscarinic acetylcholine receptor antagonists. , 2008, Journal of medicinal chemistry.
[60] Paul G Wyatt,et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.
[61] R. Copeland,et al. Drug–target residence time and its implications for lead optimization , 2006, Nature Reviews Drug Discovery.
[62] Kevan M Shokat,et al. Features of selective kinase inhibitors. , 2005, Chemistry & biology.
[63] N. Pryer,et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.
[64] J. Biggs,et al. Inhibitors of cyclin-dependent kinase and cancer , 1995, Journal of Molecular Medicine.
[65] I. Iakovidis,et al. The road ahead. , 2004, Studies in health technology and informatics.
[66] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.
[67] K. Johnson. An Update. , 1984, Journal of food protection.